Trending...
- New Rochelle: NRPD Observes May 15-21 as National Police Memorial Week
- Mayor Evans Releases His First Proposed City Budget 2022-23 Fiscal Year Budget Seeks to Chart Prosperous Future for Rochester & Address Six Administration Priorities
- Comedian Don Barnhart Brings Nightly Laughter To Jokesters Comedy Club In Las Vegas
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between June 28, 2018 and September 2, 2020, both dates inclusive (the "Class Period"). Investors have until May 13, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The Company's lead investigational product candidate is vadadustat, an oral therapy, which is in Phase 3 development for the treatment of anemia due to chronic kidney disease ("CKD") in dialysis-dependent and non-dialysis dependent ("NDD") adult patients.
Akebia's Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the "PRO2TECT Program"). The PRO2TECT Program's primary safety endpoint was defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events ("MACE").
More on Nyenta.com
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (ii) as a result, Defendants overstated the PRO2TECT Program's clinical prospects; (iii) accordingly, Defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On September 3, 2020, Akebia issued a press release announcing "top-line results" from the PRO2TECT Program, disclosing that "[v]adadustat did not meet the primary safety endpoint of the PRO2TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of [MACE.]"
On this news, Akebia's common stock price fell $7.35 per share, or 73.5%, to close at $2.65 per share on September 3, 2020.
If you purchased or otherwise acquired Akebia shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
More on Nyenta.com
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Click here to participate in the action.
Akebia is a biopharmaceutical company that focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The Company's lead investigational product candidate is vadadustat, an oral therapy, which is in Phase 3 development for the treatment of anemia due to chronic kidney disease ("CKD") in dialysis-dependent and non-dialysis dependent ("NDD") adult patients.
Akebia's Phase 3 clinical programs for vadadustat include, among others, the PRO2TECT program in NDD-CKD patients with anemia (the "PRO2TECT Program"). The PRO2TECT Program's primary safety endpoint was defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of major adverse cardiovascular events ("MACE").
More on Nyenta.com
- Wolters Kluwer's Sandeep Sacheti Named FinTech Executive Leader of the Year
- Cornerstone and Swiftlane Announce Strategic Technology Initiative to Create Safer Rental Communities in Denver
- NYC REIT Sends Letter Urging Shareholders to Vote for Company's Incumbent Director Nominee as Annual Meeting Approaches
- TUPPERWARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Tupperware Brands Corporation on Behalf of Tupperware Stockholders and Encourages Investors to Contact the Firm
- The Dog Gurus Collaborate with Blue-9 for Advancement of Dog Daycare Enrichment Programs
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) vadadustat was not as safe in treating NDD-CKD patients with anemia as Defendants had represented; (ii) as a result, Defendants overstated the PRO2TECT Program's clinical prospects; (iii) accordingly, Defendants also overstated vadadustat's overall commercial and regulatory prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
On September 3, 2020, Akebia issued a press release announcing "top-line results" from the PRO2TECT Program, disclosing that "[v]adadustat did not meet the primary safety endpoint of the PRO2TECT program, defined as non-inferiority of vadadustat versus darbepoetin alfa in time to first occurrence of [MACE.]"
On this news, Akebia's common stock price fell $7.35 per share, or 73.5%, to close at $2.65 per share on September 3, 2020.
If you purchased or otherwise acquired Akebia shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
More on Nyenta.com
- Lindsay Goldberg Completes Sale of Pixelle Specialty Solutions
- Flower City Days Horticultural at the City of Rochester Public Market Continues on Sunday, May 22
- TOKYO SKYTREE Celebrates Its 10th anniversary! Let's Pay Homage to this Japanese Landmark and World's Tallest Freestanding Broadcast Tower
- Genpact Limited Board Declares Quarterly Cash Dividend
- Yonkers Police Department promotes, appoints five members during Police Week
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Filed Under: Business
0 Comments
Latest on Nyenta.com
- M.King Media's 2nd Special Report "Black America: We Have A Problem" Is Now Streaming
- MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
- EMPIRE STATE BUILDING HONORS THE NOTORIOUS B.I.G.'S 50TH BIRTHDAY, IN PARTNERSHIP WITH THE ESTATE OF THE NOTORIOUS B.I.G.
- Community Bank System, Inc. Announces Quarterly Common Stock Dividend and Results of Annual Shareholders' Meeting
- New Rochelle Police Department Holds Annual Memorial and Awards Ceremony
- Keen-Summit Capital Partners Wins ABI Asset Sales Committee's Fourth Annual "Asset Sale of the Year"
- Yo Pitts! Foods introduces their "Snack Pack" to enjoy their delicious mustards on the go!
- Reach the World to Honor the Endurance22 Expedition with the 2022 Cronkite Award
- 286 Lenox Partners LLC and Regal 286 Lenox LLC Financial Update
- Ipsos appoints Mark Polyak as President of Analytics, Ipsos North America
- Live Webcast to Address Need for PrEP Initiation in Marginalized Populations
- Blockchain Startup Aimed at Financial Inclusion Secures 25 Million Dollar Capital Commitment
- HR Tech Awards Recognizes Valuable Contributors to Hiring, Retention, and More
- The Martini Shot Launches A Sci-Fi Martial Arts and Fashion Franchise
- 1040 Abroad: Live tax-free if you earn less than $112,000
- Egan-Jones Sponsored the Creditflux Direct Lending Forum in London
- Harlem's Fashion Row to Host 4th Annual Designer Retreat at NIKE Headquarters in New York City
- Bright Power Partners with NYC Accelerator and District of Columbia Affordable Housing Retrofit Accelerator
- Implement The Exploration Of Charity In The Virtual World Concept Till The Very End
- Hinge Announces New "Mental Health Advocates of Tomorrow" Fund to Expand Therapy Access for BIPOC and LGBTQIA+ Daters